KRAS and familial pancreatic carcinoma: KRAS is one of the most frequent oncogenic mutations present in pancreatic cancers, mostly as a single point mutation at codon 12 resulting in a constitutive activation of KRAS, which can be recognized both by T helper cells and cytotoxic T-cells and can be used as an antigen in peptide vaccination for tumors with KRAS mutations [111].